Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10000 participants.

Also called NCT06953726

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 10,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06953726
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06953726. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2032-10-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
Acronym
VALIANT-AF-T
Intervention (Drug)
Apixaban
Intervention (Drug)
Rivaroxaban
Lead sponsor
VA Office of Research and Development (class: US federal agency)
Collaborator
Food and Drug Administration (FDA) (class: US federal agency)

Record details

Record id
cardio:ct-nct06953726
Content hash
bec9f46c18d37e20f912348f15bb1060460535d5bb5cc47328732baebc767e2a